American patients would ultimately bear the cost of President Donald Trump‘s threatened tariffs on generic drugs, the CEO of Swiss pharmaceutical company Sandoz told CNBC, warning that manufacturers could be forced to raise prices or stop supplying some medicines. “Patients pay the tariff,” Sandoz CEO Richard Saynor said in an interview with CNBC during its…
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial. The company’s stock was…
Blood sample for a lipoprotein(a) test. Md Babul Hosen | Istock | Getty Images Novartis‘ failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry’s biggest drug races and rival treatments from U.S. heavyweights Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly…
Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares to new highs still has room to run. In a note to clients Wednesday, analysts at UBS raised their price target on the healthcare giant to $320 per share from $280. Their bullish view is based on three factors: (1) Top-line growth inflecting from…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,”…
Public markets are beginning to reopen for biotech companies after several years of muted activity. But the strongest companies may still be more likely to sell themselves to Big Pharma rather than testing investor appetite in an IPO, according to JPMorgan’s top healthcare dealmakers. The IPO window has reopened for high-quality biotech companies, but investors…
A photo shows a poster depicting U.S. President Donald Trump, Russian President Vladimir Putin and Chinese President Xi Jinping and reading “Breaking with Europe now of all times? NO on the SVP-Chaos-Initiative” in Thayngen, northern Switzerland, on June 1, 2026. Sebastien Bozon | Afp | Getty Images Switzerland, a wealthy country that has historically embraced…
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients. “The longer-term implications are significant,” CEO Vas Narasimhan told CNBC’s Carolin Roth. Novartis is focused on getting European and Japanese governments to quickly change…
LONDON — European stocks are expected to open higher on Tuesday as investors await Washington’s response to Iranian peace proposals and look ahead to earnings reports from several regional companies. The U.K.’s FTSE 100 index is seen opening a touch higher, with Germany’s DAX up 0.23%, France’s CAC 40 up 0.34% and Italy’s FTSE MIB 0.3%…
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a)…
